3 Stocks Boosting The Drugs Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 38 points (0.2%) at 16,236 as of Thursday, Feb. 27, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,761 issues advancing vs. 1,149 declining with 174 unchanged.

The Drugs industry currently sits up 0.4% versus the S&P 500, which is up 0.2%. Top gainers within the industry include Jazz Pharmaceuticals ( JAZZ), up 2.7%, Valeant Pharmaceuticals International ( VRX), up 1.6%, Regeneron Pharmaceuticals ( REGN), up 1.2%, Perrigo Company ( PRGO), up 1.2% and Novartis ( NVS), up 1.0%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Intercept Pharmaceuticals ( ICPT) is one of the companies pushing the Drugs industry higher today. As of noon trading, Intercept Pharmaceuticals is up $22.67 (5.6%) to $428.78 on average volume. Thus far, 319,577 shares of Intercept Pharmaceuticals exchanged hands as compared to its average daily volume of 813,600 shares. The stock has ranged in price between $401.08-$430.99 after having opened the day at $409.97 as compared to the previous trading day's close of $406.11.

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat chronic liver diseases utilizing its proprietary bile acid chemistry. Intercept Pharmaceuticals has a market cap of $7.3 billion and is part of the health care sector. Shares are up 455.2% year-to-date as of the close of trading on Wednesday. Currently there are 5 analysts who rate Intercept Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Intercept Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income. Get the full Intercept Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Amgen ( AMGN) is up $1.65 (1.4%) to $123.51 on light volume. Thus far, 852,843 shares of Amgen exchanged hands as compared to its average daily volume of 3.2 million shares. The stock has ranged in price between $121.77-$123.90 after having opened the day at $121.99 as compared to the previous trading day's close of $121.86.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $93.9 billion and is part of the health care sector. Shares are up 9.0% year-to-date as of the close of trading on Wednesday. Currently there are 8 analysts who rate Amgen a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Pfizer ( PFE) is up $0.17 (0.5%) to $32.16 on light volume. Thus far, 9.0 million shares of Pfizer exchanged hands as compared to its average daily volume of 26.4 million shares. The stock has ranged in price between $31.83-$32.24 after having opened the day at $31.87 as compared to the previous trading day's close of $31.99.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $206.7 billion and is part of the health care sector. Shares are up 4.4% year-to-date as of the close of trading on Wednesday. Currently there are 8 analysts who rate Pfizer a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

GE Confirms $11.1 Billion Transportation Merger With Wabtec

GE Confirms $11.1 Billion Transportation Merger With Wabtec